Lung cancer is one of the leading causes of cancer mortality worldwide. The main types of lung cancer are small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC). In this work, a computational method was proposed for identifying lung-cancer-related genes with a shortest path approach in a protein-protein interaction (PPI) network. Based on the PPI data from STRING, a weighted PPI ne...

Optimal management of nonsmall cell lung cancer (NSCLC) depends on tissue diagnosis and accurate staging. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is minimally invasive and provides cytological confirmation of malignant mediastinal disease. The aim was to assess the accuracy of EUS-FNA in cases of enlarged mediastinal lymphadenopathy (LN) of unknown aetiology and in the sta...

background: lung cancer is the most common cause of cancer death worldwide with an annual mortality rate of more than 1.3 million worldwide. we aimed to analyze the clinicopathological features of patients with non-small-cell lung cancer (nsclc) in west of iran. methods: 64 patients with nsclc who referred to our clinic were analyzed. sex, age, histopathology, location of the tumor, treatment, ...

Updates to the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) 2021 include recommendations biomarker testing in all appropriate patients with newly diagnosed advanced lung cancer, including squamous cell cancer. When a targetable genetic alteration is detected, recommend treatment first-line therapy targeted that alteration. The guidelines contain new information on use of adjuvant osim...

Pemetrexed (ALIMTA, LY231514, MTA) is a novel multitargeted antifolate that is currently approved for the treatment of metastatic nonsmall cell lung cancer (NSCLC). Recent evidence reveals that the drug's efficacy is limited to nonsquamous lung cancer histology. As we further understand the drug's mechanisms of action, new genomic and proteomic evidence is shedding light on why some patients re...

New biological factors have not been extensively studied in stage III nonsmall cell lung cancer (NSCLC). The aim of the present retrospective study was to determine the role of epidermal growth factor receptor (EGF-R) as a prognostic factor in stage III NSCLC, in addition to the stage and other known clinical factors. Clinical characteristics were retrieved from the patients' charts. Membrane i...

To date, lung cancer is the leading cause of cancer-related death worldwide, among which nonsmall cell lung cancer (NSCLC) comprises about 85%. Taking into account the side effects of surgery, radiation, platinum-based doublet chemotherapy, and the growth self-sufficiency characteristic of cancer cells, drugs have been discovered toward growth factor receptor (GFR) to treat NSCLC. As expected, ...

Abstract Objectives Japan’s healthcare expenditures, especially on oncology, are rapidly growing; however, there scant data actual costs and cost-effectiveness in the real world. The aim was to assess medical outcomes of patients with advanced lung cancer. Methods We retrospectively investigated all who were diagnosed cancer at Japanese Red Cross Medical Center between 1 January 2008 31 Decembe...

The association between hypocholesterolemia and lung cancer risk has been confirmed in some studies. The purpose of the study was to determine whether preoperative hypocholesterolemia (below normal range) is a prognostic factor for survival after nonsmall cell lung cancer (NSCLC) resection. Two hundred and sixty-two consecutive cases of resected NSCLC with a followup period for more than 5 year...

Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of nonsmall cell lung cancer. Dai L1,2,3, Qu Y3,4, Li J2, Wang X1, Wang K3,5, Wang P3,5, Jiang BH6, Zhang J1,2,3. Oncotarget. 2017 Apr 12. doi: 10.18632/oncotarget.17067. [Epub ahead of print] PURPOSE: Lung ca...